



## **Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010**

October 13, 2010

ROCKVILLE, Md., Oct 13, 2010 (BUSINESS WIRE) --

Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for third quarter 2010 on Thursday November 4, 2010, after market close.

Company management will host a conference call at 5:00 pm Eastern on November 4, 2010 to discuss the financial results for the third quarter and first nine months of 2010, recent business developments and the forecast for 2010. The conference call will be accessible by dialing **888/713-4211** or **617/213-4864** (international) and providing passcode **50859780**. A webcast of the conference call will be accessible from the Company's website at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com), under "Investors".

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration, while not mandatory, can be accessed using the following website: <https://www.theconferencingservice.com/prereg/key.process?key=PNP49E4W7>.

A replay of the conference call will be accessible, approximately one hour following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using the passcode 97521313. The replay will be available through November 18. The webcast will be archived on the company's website, [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com), under "Investors".

### **About Emergent BioSolutions Inc.**

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax<sup>®</sup> (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

#### **Investors Contact:**

Robert G. Burrows

Vice President, Investor Relations

301-795-1877

[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

or

#### **Media Contact:**

Tracey Schmitt

Vice President, Corporate Communications

301-795-1800

[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)